Cargando…

Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib

SIMPLE SUMMARY: Persistence of infused cells is an important factor that dictates the outcome of adoptive cellular therapy (ACT). DNT therapy is a novel form of ACT with promising result in treating relapsed or refractory AML in preclinical and early clinical studies. However, in vivo kinetics of hu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Hyeonjeong, Lee, Jong Bok, Khatri, Ismat, Na, Yoosu, D’Souza, Cheryl, Arruda, Andrea, Minden, Mark D., Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533698/ https://www.ncbi.nlm.nih.gov/pubmed/34680188 http://dx.doi.org/10.3390/cancers13205039

Ejemplares similares

Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
por: Fang, Karen Kai-Lin, et al.
Publicado: (2023)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy
por: Chen, Branson, et al.
Publicado: (2018)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells
por: Hock, Barry D., et al.
Publicado: (2017)

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
por: Maffei, Rossana, et al.
Publicado: (2015)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
por: Modi, Prexy, et al.
Publicado: (2017)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat, Yazan F, et al.
Publicado: (2016)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
por: Burke, Russell T, et al.
Publicado: (2014)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

State-of-Art of Cellular Therapy for Acute Leukemia
por: Lee, Jong-Bok, et al.
Publicado: (2021)

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
por: Ghia, Paolo, et al.
Publicado: (2020)

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia
por: Laverdière, Isabelle, et al.
Publicado: (2018)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
por: Alflen, Astrid, et al.
Publicado: (2018)

Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019)

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
por: Yang, Shida, et al.
Publicado: (2016)

Idelalisib may have the potential to increase radiotherapy side effects
por: Gryc, Thomas, et al.
Publicado: (2017)

A novel strategy for the manufacture of idelalisib: controlling the formation of an enantiomer
por: Mekala, Nagaraju, et al.
Publicado: (2018)

An unusual case of Idelalisib‐related pneumonitis with severe respiratory failure
por: Sousa, Domingos, et al.
Publicado: (2020)

Management of adverse events associated with idelalisib treatment: expert panel opinion
por: Coutré, Steven E., et al.
Publicado: (2015)

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia
por: Primo, Daniel, et al.
Publicado: (2018)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice
por: Driscoll, Nancy
Publicado: (2016)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
por: de Weerdt, Iris, et al.
Publicado: (2017)

Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma
por: Hengeveld, Paul J, et al.
Publicado: (2020)

Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15
por: Yao, Junlin, et al.
Publicado: (2019)

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion
por: Coelho, H., et al.
Publicado: (2017)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
por: Somoza, John R., et al.
Publicado: (2015)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2hqqdfaltjc76tkpf0re0iv4bb